- $94.61bn
- $95.09bn
- $10.21bn
- 66
- 40
- 100
- 78
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 23.59 | ||
PEG Ratio (f) | 2.46 | ||
EPS Growth (f) | 10.62% | ||
Dividend Yield (f) | 3.78% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.57 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 26.31 | ||
Price to Sales | 9.27 | ||
EV to EBITDA | 11.39 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 22.8% | ||
Return on Equity | 13.08% | ||
Operating Margin | 78.46% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 5,066.3 | 4,996.6 | 7,217.8 | 10,854.2 | 10,209.2 | 6,517.33 | 6,800.38 | 13.14% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -0.61 | +8.19 | +16.45 | +19.78 | +9.15 | +13.42 | +4.84 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
CME Group Inc. provides a derivatives marketplace. The Company enables clients to trade futures, options, cash and over the counter (OTC) markets, optimize portfolios, and analyze data. It exchanges offer a range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange (FX), energy, agricultural products and metals. It offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and FX trading on the EBS platform. In addition, it operates central counterparty clearing provider, CME Clearing. Its products provide a means for hedging, speculation and asset allocation related to the risks associated with, among other things, interest rate sensitive instruments, and changes in the prices of agricultural, energy and metal commodities. It provides clearing and settlement services for a range of exchange-traded futures and options on futures contracts and OTC derivatives.
Directors
- Terrence Duffy CHM (62)
- Charles Carey VCH (67)
- John Pietrowicz CFO (57)
- Sunil Cutinho CEX (49)
- Hilda Piell CHO (53)
- Jack Tobin CAO (57)
- Kevin Kometer CIO (56)
- Kathleen Cronin GCN (57)
- Julie Holzrichter SMD (52)
- Derek Sammann SMD (52)
- Sean Tully SMD (57)
- Kendal Vroman SMD (49)
- Julie Winkler SMD (46)
- Daniel Glickman LED (76)
- Michael Dennis DRC (40)
- Bryan Durkin DRC (59)
- Timothy Bitsberger IND (61)
- Dennis Chookaszian IND (77)
- Elizabeth Cook IND (60)
- Ana Dutra IND (56)
- Martin Gepsman IND (68)
- Larry Gerdes IND (72)
- William Hobert IND (57)
- Daniel Kaye IND (66)
- Phyllis Lockett IND (55)
- Deborah Lucas IND (62)
- Patrick Maloney IND (59)
- Patrick Mulchrone IND (63)
- Terry Savage IND (76)
- Rahael Seifu IND (39)
- William Shepard IND (74)
- Howard Siegel IND (64)
- Dennis Suskind IND (78)
- Robert Tierney IND (45)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 2nd, 2001
- Public Since
- December 6th, 2002
- No. of Shareholders
- 5,350
- No. of Employees
- 3,760
- Sector
- Investment Banking & Investment Services
- Industry
- Financials
- Exchange
NASDAQ Global Select Market
- Shares in Issue
- 360,382,710

- Address
- 20 S. Wacker Dr., CHICAGO, 60606
- Web
- https://www.cmegroup.com/
- Phone
- +1 3129301000
- Auditors
- Ernst & Young LLP
Latest News for CME
Upcoming Events for CME
Q1 2025 CME Group Inc Earnings Call
Q1 2025 CME Group Inc Earnings Release
CME Group Inc Annual Shareholders Meeting
CME Group Inc Annual Shareholders Meeting
Q2 2025 CME Group Inc Earnings Release
Similar to CME
ACI Worldwide
NASDAQ Global Select Market
Affirm Holdings
NASDAQ Global Select Market
Applied Digital
NASDAQ Global Select Market
Ares Capital
NASDAQ Global Select Market
Argo Blockchain
NASDAQ Global Select Market
FAQ
As of Today at 19:59 UTC, shares in CME are trading at $262.53. This share price information is delayed by 15 minutes.
Shares in CME last closed at $262.53 and the price had moved by +25.96% over the past 365 days. In terms of relative price strength the CME share price has outperformed the S&P500 Index by +18.44% over the past year.
The overall consensus recommendation for CME is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe CME dividend yield is 3.96% based on the trailing twelve month period.
Last year, CME paid a total dividend of $10.40, and it currently has a trailing dividend yield of 3.96%. We do not have any data on when CME is to next pay dividends.
We do not have data on when CME is to next pay dividends. The historic dividend yield on CME shares is currently 3.96%.
To buy shares in CME you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $262.53, shares in CME had a market capitalisation of $94.61bn.
Here are the trading details for CME:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CME
Based on an overall assessment of its quality, value and momentum CME is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in CME is $272.07. That is 3.63% above the last closing price of $262.53.
Analysts covering CME currently have a consensus Earnings Per Share (EPS) forecast of $10.97 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CME. Over the past six months, its share price has outperformed the S&P500 Index by +27.42%.
As of the last closing price of $262.53, shares in CME were trading +14.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CME PE ratio based on its reported earnings over the past 12 months is 23.59. The shares last closed at $262.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CME's management team is headed by:
- Terrence Duffy - CHM
- Charles Carey - VCH
- John Pietrowicz - CFO
- Sunil Cutinho - CEX
- Hilda Piell - CHO
- Jack Tobin - CAO
- Kevin Kometer - CIO
- Kathleen Cronin - GCN
- Julie Holzrichter - SMD
- Derek Sammann - SMD
- Sean Tully - SMD
- Kendal Vroman - SMD
- Julie Winkler - SMD
- Daniel Glickman - LED
- Michael Dennis - DRC
- Bryan Durkin - DRC
- Timothy Bitsberger - IND
- Dennis Chookaszian - IND
- Elizabeth Cook - IND
- Ana Dutra - IND
- Martin Gepsman - IND
- Larry Gerdes - IND
- William Hobert - IND
- Daniel Kaye - IND
- Phyllis Lockett - IND
- Deborah Lucas - IND
- Patrick Maloney - IND
- Patrick Mulchrone - IND
- Terry Savage - IND
- Rahael Seifu - IND
- William Shepard - IND
- Howard Siegel - IND
- Dennis Suskind - IND
- Robert Tierney - IND